School of Public Health, University of Alberta, Edmonton, AB, Canada.
Ann Surg Oncol. 2012 Mar;19(3):714-21. doi: 10.1245/s10434-011-2063-y. Epub 2011 Sep 16.
Recent population-based studies in Alberta, Canada, found that approximately 50% of patients with stage III colon or stages II/III rectal adenocarcinoma did not receive guideline-recommended treatment (surgery plus chemotherapy or chemoradiation); a primary reason was not having an oncologist consult. We assessed the relationship between the hospital where the surgery was performed and the probability of a patient not having an oncologist consult.
All patients diagnosed with stage III colon or stage II/III rectal adenocarcinoma between 2002 and 2005 in Alberta who had surgery were identified from the Alberta Cancer Registry and included in the study. Multivariable logistic regression modeling with hospitals as random effects was used to estimate cancer-type-specific odds ratios of not having an oncologist consult for each hospital, adjusted for age, sex, and comorbidities, relative to the overall nonconsultation rate.
Overall, 21% of stage III colon, 25% of stage II rectal, and 13% of stage III rectal adenocarcinoma patients did not have an oncologist consult. Rates varied appreciably across hospitals and between cancer types within hospitals, even after the case-mix adjustment (adjusted odds ratios of nonconsultation ranged from 0.4 to 8.1). Small hospitals that performed 12 or fewer surgeries had nearly 100% consultation rates.
The variation in oncologist-consult rates, particularly for stage II rectal cancer patients, is concerning. We are presenting the findings to the surgical community and discussing interventions to improve oncologist-consult rates.
最近在加拿大阿尔伯塔省进行的基于人群的研究发现,大约有 50%的 III 期结肠癌或 II/III 期直肠腺癌患者未接受指南推荐的治疗(手术加化疗或放化疗);主要原因是没有肿瘤医生咨询。我们评估了手术医院与患者未接受肿瘤医生咨询的概率之间的关系。
从阿尔伯塔癌症登记处确定了 2002 年至 2005 年间在阿尔伯塔省诊断为 III 期结肠癌或 II/III 期直肠腺癌且接受手术的所有患者,并将其纳入研究。使用医院为随机效应的多变量逻辑回归模型,估计每个医院未进行肿瘤医生咨询的癌症类型特异性比值比,调整年龄、性别和合并症,与总体非咨询率相比。
总体而言,31%的 III 期结肠癌、25%的 II 期直肠腺癌和 13%的 III 期直肠腺癌患者未进行肿瘤医生咨询。即使在病例组合调整后,医院之间和医院内不同癌症类型之间的差异仍然很大(未咨询的调整比值比范围从 0.4 到 8.1)。手术量少于 12 例的小医院咨询率接近 100%。
肿瘤医生咨询率的差异,特别是 II 期直肠腺癌患者的咨询率,令人担忧。我们正在向外科医生群体介绍这些发现,并讨论提高肿瘤医生咨询率的干预措施。